Drug intelligence / Profile preview

LF-MSC-GT010

Development stage: Unknown
Lead developer: Shanghai Laifu Life Science Technology
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Bronchoscopic Injection

Overview

LF-MSC-GT010 is an investigational cell-based gene therapy developed by Shanghai LIFE Medical Science and Technology for the treatment of coronary heart disease and heart failure. The therapy utilizes mesenchymal stem cells (MSCs) as a delivery vehicle, which are genetically modified ex vivo using a lentiviral vector to express therapeutic genes. This approach combines the inherent regenerative and immunomodulatory properties of MSCs with the targeted effects of gene therapy to promote myocardial repair and improve cardiac function. It is currently in Phase 1 clinical development through investigator-initiated trials (IIT).

Beyond the preview

Go deeper on LF-MSC-GT010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LF-MSC-GT010.

Explore the full profile